Ancora Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 2 trial initiated for depression treatment targeting specific biomarker

EmbarkNeuro, a neuroscience biotech company formerly known as Ancora Bio, announced its phase 2 trial is under way for ANC-501, a first-in-class vasopressin 1b receptor antagonist for the treatment of major depressive disorder. The trial, an 8-week single-arm study, will assess the efficacy of ANC-501 when added to a standard antidepressant therapy in patients with biomarker-confirmed disruption

Stephen kanesShenaz baghaAncora bio

Ophthalmologists should encourage patients to undergo SLT for glaucoma treatment

CHICAGO — Evidence suggests that selective laser trabeculoplasty could be the standard of care for patients with glaucoma, according to a speaker here.

United statesChristine klimanskisJonathans myersJohnathans myersByanthony definoAncora bioAmerican academy of ophthalmologyAmerican academyGlaucoma subspecialty day

Fierce Pharma Asia—Fujifilm, WuXi STA plan major expansions; Hanmi s GLP-1 posts heart data; BeiGene plots $3B China IPO

Fierce Pharma Asia—Fujifilm, WuXi STA plan major expansions; Hanmi s GLP-1 posts heart data; BeiGene plots $3B China IPO
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesArrivent biopharmaAllist pharmaJoe jimenezAncora bioAditum bioFujifilm diosynth biotechnologiesWuxi apptechHanmi pharmaceuticalஹாங் காங்ஒன்றுபட்டது மாநிலங்களில்மிடில் டவுன்ஓஹோ ஜிமெனெஸ்ஹன்மி மருந்து

Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment-Resistant Depression

Share this article Share this article OAKLAND, Calif., June 30, 2021 /PRNewswire/ Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Ancora Bio, a portfolio company developing a new therapy for treatment-resistant depression. Ancora Bio is being formed following the successful in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd. Depression is unfortunately one of the fastest growing mental health challenges, exacerbated by the past 12 months of isolation during the Covid-19 pandemic, said Joe Jimenez, Co-Founder and Managing Director of Aditum Bio. Dr. Mark Fishman, Co-Founder and Chair of the Medical and Scientific Advisory Boards added, ANC-501 has been shown to impact a definable subset of patients with treatment-resistant depression.

John doerrMichael moritzMark fishmanJoe jimenezAncora bioAditum bioNovartis institutes for biomedical researchTaisho pharmaceutical co ltdSequoia capitalNovartis institutesBiomedical researchManaging directorScientific advisory boardsThrive capitalஜான் தோேறுற்மைக்கேல் மோரிட்ஸ்